Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AD/PD 2022 | New drugs for treatment of Parkinson’s disease

Fabrizio Stocchi, MD, PhD, IRCCS San Raffaele Rome, Sapienza University of Rome, Rome, Italy, gives an insight into the new agents available for the treatment of Parkinson’s disease (PD). Safinamide, opicapone, sublingual apomorphine, inhalation levodopa, and slow-release preparation of levodopa have already entered or are just entering the PD market. Safinamide is an inhibitor of monoamine oxidase-B (MAO-B) and opicapone is an inhibitor of catechol-O-methyltransferase (COMT), both of which act to help levodopa work better through reduction of necessary oral levodopa intake and “OFF” times. Opicapone may also be able to reduce the risk of motor fluctuations and dyskinesias in patients who are not already suffering with these symptoms. This interview took place at the AD/PD™ 2022 Conference in Barcelona, Spain.

Disclosures

Sunovion, Neuroderm, Abbvie, Britannia, Lusofarmaco, Ever Pharma, BIAL Pharma, Roche, Biogen, IRLAB, Chiese Ltd., GlaxoSmithKline Plc., Impax Laboratories Inc., Lundbeck Ltd., Teva UK Limited, UCB Pharma Ltd., Merck & Co. Inc, Zambon Pharma, Novartis AG